Coexpression of survivin and PCNA in pituitary tumors and normal pituitary

Neuroendocrinology Letters

Volumn 30, Issue 4, 2009, Pages 477-481

  Wasko, Ryszard ^a   Waligorska Stachura, Joanna ^a   Jankowska, Anna ^a   Warchol, Jerzy B ^a   Liebert, Wlodzimierz ^a   Sowinski, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Immunohistochemistry; Pituitary tumors; Survivin

Indexed keywords

SURVIVIN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; NEUROSURGERY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR CELL;

EID: 76049094708     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Holcik M. (2002). The IAP proteins. Trends Genet 18; 537-538
2. Roy N et al. (1997). The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16; 6914-6925
3. La Casse EC et al. (1998). The inhibitors of apoptosis (IAPs) amd their emerging role in cancer. Oncogene. 17; 3247-59
4. Altieri DC. (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3;46-54
5. Marusawa H et al. (2003). HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22; 2729-40
6. Tamm I et al. (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax caspases, and anticancer drugs. Cancer Res. 58; 5315-20
7. Li F, Altieri DC. (1999). The cancer anti-apoptosis mouse survivin gene: characerization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 59; 3143-51
8. O'Connor DS et at. (2000a). Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97; 13103-07
9. O'Connor DS et al. (2000). Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 156; 393-8
10. Ambrosini G et al. (1998). Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 273; 11177-82
11. Deguchi M et al. (2002). Expression of survivin during liver regeneration. Biochem Biophys Res Commun. 297; 59-64
12. Chiou SK et al. (2003). Survivin expression in the stomach: implications for mucosal intergrity and protection. Biochem Biophys Res Commun. 305; 374-379
13. Wang Y et al. (2004). Survivin expression in rat testis is up-regulated by stem-cell factor. Mol Cell Endocrinol. 218; 165-174
14. Hassounah M et al. (2005). Benign tumors from the human nervous system express high levels of survivin and are resistant to spontaneous and radiation-induced apoptosis. J NeuroOncol. 72; 203-208
15. Jankowska A et al. (2008). Survivin products in pituitary tumors. Neuroendocrinol Lett. 6; 807
16. Hengartner MO. (1998). Nature death cycle and swiss army knives. Nature. 391; 441-442
17. Sasaki T et al. (2002). Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol. 104; 105-9
18. Fukuda S et al. (2006). Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 5; 1087-1098
19. Li F et al. (2005). Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer. 114; 5-9-12
20. Fields et al. (2004). Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 17; 1378-85
21. Shinohara et al. (2005). Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer. 103; 1685-92
22. Kawasaki H et al. (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58; 5071-4
23. Tanaka K et al. (2000). Expression of survivivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 6; 127-34
24. Zaffaroni N et al. (2002). Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat. 5; 65-72
25. Tran J et al. (2002). A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99; 4349-54
26. Swana HS et al. (1999). Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 341; 452-3
27. Pawlikowski M et al. (2006). Proliferatin cell nuclear antygen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem Cytobiol. 44; 37-41
28. Hsu DW et al. (1993). Significance of proliferating cell nulear antygen index in predicting pituiary recurrence. J Neurosurg. 78; 753-761
29. Kayaselcuk F et al. (2004). The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome. J Neuro Oncol. 67; 209-214